PicoScope 7 Automotive
Available for Windows, Mac, and Linux, the next evolution of our diagnostic scope software is now available.
PicoScope 7 Automotive
Available for Windows, Mac, and Linux, the next evolution of our diagnostic scope software is now available.
At Pico, we have distributors in over 50 countries. Find your local distributor here.
All Articles
All of our expert articles, blogs and whitepapers in one place
Application Notes
Details of some of the many applications for our products.
Case Studies
Explore our case studies to see how organizations leverage our automotive solutions
Guided Tests
A library of examples on how to perform tests using PicoScope
Company News
Get to know the people behind our brand with the latest updates from our team.
Product News
Stay up-to-date with the latest Pico product news.
Knowledge Base
Everything you need to know about our products and software.
Training
A library of videos, articles, guides and information on how to use PicoScope
At Pico, we have distributors in over 50 countries. Find your local distributor here.
About Us
Go to the about page to learn more about Pico TechnologyExhibitions
Go to the exhibitions page to see where Pico Technology will be exhibiting nextHistory of Pico products
Go to the history page to learn more about the history of Pico TechnologyHow to order
Go to the how to order page to learn how to order Pico Technology productsLegal information
Go to the legal information page to learn more about the legal information of Pico TechnologyEnvironment & PicoPlanet
Go to the environment page to learn more about the environment and Pico PlanetDespite strong fundamentals, many analysts recommend caution in the immediate term: GSK (GSK) Earnings Expected to Grow: Should You Buy?
For investors with a longer time horizon, GSK presents a compelling "Buy" narrative centered on its successful pivot to a high-margin, pure-play pharmaceutical company: gsk buy or sell
Management has reaffirmed its 2026 outlook, expecting core EPS growth of 7% to 9%. Key growth drivers include Arexvy (RSV vaccine) and expansion into specialty medicines like HIV and Oncology. Despite strong fundamentals
Several valuation models suggest the stock is significantly undervalued. Discounted Cash Flow (DCF) analyses from Yahoo Finance estimate the stock is trading at a ~52-53% discount to its fair value. gsk buy or sell